Abstract Number: 0012 • ACR Convergence 2020
Experiences of Patients with Rheumatic Diseases in the US During the Early Months of the COVID-19 Pandemic
Background/Purpose: Patients with rheumatic diseases such as RA and lupus have increased risk of infection and are treated with medications that may increase this risk…Abstract Number: 0158 • ACR Convergence 2020
Relationships Between Disease Patterns in RA and Rheumatology Treatment
Background/Purpose: We previously showed rheumatoid arthritis (RA) patients report diversity in disease activity (DA) patterns that may be associated with treatment response. Patients who describe…Abstract Number: 0324 • ACR Convergence 2020
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome…Abstract Number: 0613 • ACR Convergence 2020
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…Abstract Number: 1126 • ACR Convergence 2020
A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study
Background/Purpose: Mindfulness Based Interventions (MBIs) are well-established self-management programs shown to be beneficial for pain, depression, and anxiety that focus on learning how to respond…Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…Abstract Number: 1469 • ACR Convergence 2020
Characteristics of Adult Patients with Rheumatic Diseases During the COVID-19 Pandemic: Data from an International Patient Survey
Background/Purpose: Patients with rheumatic diseases are at increased risk of infection due to immune dysregulation and the use of immunosuppression. It is unknown whether they…Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…Abstract Number: PP08 • ACR Convergence 2020
Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up
Background/Purpose: The COVID-19 Global Rheumatology Alliance (GRA) is a volunteer-driven organization that originated in response to the global pandemic. It was created to improve patient…Abstract Number: 0135 • ACR Convergence 2020
Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
Background/Purpose: Understanding patient satisfaction with their rheumatologist and the drivers of satisfaction is crucial to improving doctor-patient interactions, helping patients get on the right treatment…Abstract Number: 0159 • ACR Convergence 2020
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with…Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…Abstract Number: 1127 • ACR Convergence 2020
Association of Health Literacy and Numeracy with Patient Reported Psychological Outcomes
Background/Purpose: Over 33 percent of American adults have low health literacy, which limits their ability to understand basic health information and make healthcare decisions. A…Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…